Researchers at the University of Washington described a new class of engineered proteins that perform Boolean logic gating—AND, OR and YES—to control drug localization and release in response to multiple biological cues. The proof‑of‑principle work, published in Nature Chemical Biology, used self‑folding tails that change conformation with local enzymes, pH or disease‑associated markers to gate therapeutic activation. Senior author Cole DeForest reported advances in recombinant expression that accelerate production and increase logical complexity, shifting the approach from laborious chemical syntheses to scalable biologic manufacture. The system allows proteins to act as autonomous decision‑makers, releasing cargo only when specified combinations of signals are present. The platform could reduce off‑target toxicity and improve therapeutic indices for immunotherapies and targeted agents, while faster recombinant workflows remove a major bottleneck in moving complex molecular logic devices toward preclinical testing.